https://www.selleckchem.com/products/px-478-2hcl.html st of our knowledge. The results suggest that (a) SDDRO can substantially improve the FLASH-dose rate coverage (e.g., in terms of dose rate volume histogram) compared to IMPT for the purpose of normal tissue sparing while preserving the dose distribution and (b) the combination of hypofractionation and multiple beams can further considerably improve the SDDRO plan quality in terms of both dose and dose rate distribution. We have developed a joint dose and dose rate optimization method for FLASH proton RT, namely SDDRO, which is first-of-its-kind to the best of our knowledge. The results suggest that (a) SDDRO can substantially improve the FLASH-dose rate coverage (e.g., in terms of dose rate volume histogram) compared to IMPT for the purpose of normal tissue sparing while preserving the dose distribution and (b) the combination of hypofractionation and multiple beams can further considerably improve the SDDRO plan quality in terms of both dose and dose rate distribution. This study aimed to investigate the value of high-flow nasal cannula (HNFC) oxygen therapy in treating patients with severe novel coronavirus pneumonia (COVID-19). The clinical data of 22 patients with severe COVID-19 were collected. The heart rate (HR), respiratory rate (RR) and oxygenation index (PO /FiO ) at 0, 6, 24 and 72hours after treatment were compared between the HFNC oxygen therapy group and the conventional oxygen therapy (COT) group. In addition, the white blood cell (WBC) count, lymphocyte (L) count, C-reactive protein (CRP) and procalcitonin (PCT) were compared before and at 72hours after oxygen therapy treatment. The differences at 0hours between the two groups were not statistically significant. Compared with COT group,in the HFNC oxygen therapy group, HR, RR and PaO /FiO were better at 6hours after treatment, PaO /FiO was better at 24 and 72hours. After 72hours, L and CRP had improved in the HFNC oxygen therapy group compared wi